The Latest and Greatest in Depression and Schizophrenia

All sessions will be held in Pacific Time (PT).



Saturday, April 29, 2023

7:00 am - 8:00 am

What’s New? Exciting Developments in Novel Science for Schizophrenia

Andrew J. Cutler, MD and Jonathan M. Meyer, MD

Dopaminergic dysregulation has historically been the mainstay for hypothesized neuropathology in schizophrenia. Here, Drs. Andrew Cutler and Jonathan Meyer will discuss advances in that hypothesis and how novel medications with targets outside of the dopamine system may improve efficacy and tolerability when treating schizophrenia.

8:00 am - 9:00 am

Industry Symposium†

Sponsored by TBD

9:00 am – 9:05 am

Break

9:05 am – 9:35 am

Poster Session†

Sponsored by Idorsia Pharmaceuticals

9:35 am - 10:35 am

What's New? Exciting Developments in Novel Science for Depression

Leslie Citrome, MD, MPH and Roger S. McIntyre, MD, FRCPC

There are many new and exciting advances in the options available to treat depression. These novel medications go beyond the monoaminergic hypothesis of depression and may have faster onset of action, greater efficacy and improved tolerability. Join Drs. Leslie Citrome and Roger McIntyre as they explore these latest advances and provide strategies for implementing them into practice.

10:35 am - 11:00 am

Live Panel Q&A

Andrew J. Cutler, MD; Jonathan M. Meyer, MD; Leslie Citrome, MD, MPH; and Roger S. McIntyre, MD, FRCPC



†The content of all non-CME/CE events (Industry Symposia, Disease State Sessions, and Poster Sessions) and the views expressed therein are those of the presenting entity and not of NEI. These events are not part of the scientific program and do not provide CME/CE credit. By opening a non-CME/CE event, the attendee opts in to receive follow-up information from the commercial sponsor.



Program Faculty

Leslie Citrome, MD, MPH


Clinical Professor, Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY


Leslie Citrome, MD, MPH, is Clinical Professor of Psychiatry and Behavioral Sciences at New York Medical College in Valhalla, New York and has a private practice in Pomona, New York. He is the Editor-in-Chief of the International Journal of Clinical Practice, published by Wiley. Dr. Citrome was the founding Director of the Clinical Research and Evaluation Facility at the Nathan S. Kline Institute for Psychiatric Research in Orangeburg, New York, and after nearly two decades of government service as a researcher in the psychopharmacological treatment of severe mental disorders, Dr. Citrome is now engaged as a consultant in clinical trial design and interpretation.

Dr. Citrome is a member of the Board of Directors of the American Society of Clinical Psychopharmacology. Main areas of interest include schizophrenia, bipolar disorder, and major depressive disorder. He is a frequent lecturer on the quantitative assessment of clinical trial results using the evidence-based medicine metrics of number needed to treat and number needed to harm.

Dr. Citrome is the author or co-author of over 400 research reports, reviews, and chapters in the scientific literature, is on the editorial board of 13 different medical journals, reviews for over 90 journals, and has lectured extensively throughout the USA, Canada, Europe, and Asia.

read more +

Andrew J. Cutler, MD


Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY

Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA


Andrew J. Cutler, MD, attended Haverford College in Philadelphia, Pennsylvania, earning a BS in Biology. He received his MD from the University of Virginia School of Medicine, where he was also elected to the Alpha Omega Alpha (AOA) honor medical society and received the Merck Award for outstanding medical scholarship. He completed his Medical internship, Internal Medicine residency and Psychiatry residency at the University of Virginia Medical Center, where he served as Chief Resident of Psychiatric Medicine and did research on dopamine receptor pharmacology in the lab of James P. Bennett, MD, PhD.  Dr. Cutler then served as the first Assistant Professor and Director of Psychiatric Medicine at the University of Chicago. He has been Board Certified in both Internal Medicine and Psychiatry.

Dr. Cutler has been Principal Investigator (PI) on over 400 psychiatric and medical clinical trials.

Dr. Cutler has authored over 50 peer-reviewed scientific articles and has authored and presented over 100 abstracts/posters at various scientific meetings. He serves as a peer reviewer for many prestigious scientific and medical journals and serves or has served on several Editorial Boards.  He has chaired or attended over 200 Scientific Advisory Boards, delivered over 3,000 pharmaceutical promotional talks and over 250 invited CME lectures and Grand Rounds presentations.  He has also done over 30 national satellite television medical education broadcasts and over 100 national medical web conferences.

Dr. Cutler is a member of several professional organizations, including the American Psychiatric Association, the Florida Psychiatric Society and the American Medical Association. He has earned the Certified Physician Investigator (CPI) distinction from the Academy of Physicians in Clinical Research (formerly the Academy of Pharmaceutical Physicians and Investigators). He is a Fellow of the American Psychiatric Association and the Academy of Psychosomatic Medicine. He has received several professional honors and awards including the Merck Award for outstanding medical scholarship, the University of Virginia Pride Award for outstanding patient care, the William Sorum Award from the American Psychiatric Association, the Outstanding Congressional Fellow Award from the 103rd U.S. Congress, a citation from Florida Hospital for outstanding patient care and the Distinguished Clinical Professional Award from the Mental Health Association of Central Florida. He presents research posters and teaches at professional meetings and has published numerous articles in scientific and medical journals. Dr. Cutler frequently gives talks to community groups and national audiences, and often appears as a medical expert in the local and national media. 

read more +

Roger S. McIntyre, MD, FRCPC


Professor, Departments of Psychiatry and of Pharmacology, University of Toronto, Toronto, ON, Canada

Chairman and Executive Director, Brain and Cognition Discovery Foundation, Toronto, ON, Canada

Director and Chair, Scientific Advisory Board, Depression and Bipolar Support Alliance, Chicago, IL, USA

Clinical Professor, State University of New York Upstate Medical University, Syracuse, NY, USA

Clinical Professor, Department of Psychiatry and Neurosciences, University of California School of Medicine, Riverside, CA, USA

Professor and Nanshan Scholar, Guangzhou Medical University, Guangzhou, China

Adjunct Professor, College of Medicine, Korea University, Seoul, South Korea

Visiting Professor, College of Medicine, University of the Philippines, Manila, Philippines


Roger S. McIntyre, MD, FRCPC, is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. 

Dr. McIntyre was named by Thomson Reuters in 2014 and 2015, as one of “The World’s Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade.    

Dr. McIntyre is involved in multiple research endeavors which primarily aim to characterize the association between mood disorders, notably cognitive function and medical comorbidity. His works broadly aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment. 

Dr. McIntyre is extensively involved in medical education. He is a highly sought-after speaker at both national and international meetings. He has received several teaching awards from the University of Toronto, Department of Psychiatry and has been a recipient of the joint Canadian Psychiatric Association (CPA) / Council of Psychiatric Continuing Education Award for the Most Outstanding Continuing Education Activity in Psychiatry in Canada.

Dr. McIntyre is a contributor to the “Florida Medicaid Drug Therapy Management Program for Behavioral Health: Guidelines for the treatment of adults with Major Depressive Disorder and Bipolar Disorder”. Dr. McIntyre is also the co-chair of the Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force on the Treatment of Comorbidity in Adults with Major Depressive Disorder or Bipolar Disorder and as well a contributor to the “CANMAT Guidelines for the Treatment of Depressive Disorders and Bipolar Disorders”. Dr. McIntyre has published hundreds of peer-reviewed articles and has edited and/or co-edited several textbooks on mood disorders.

Dr. McIntyre completed his medical degree at Dalhousie University. He received his Psychiatry residency training and Fellowship in Psychiatric Pharmacology at the University of Toronto.

read more +

Jonathan M. Meyer, MD


Voluntary Clinical Professor, Department of Psychiatry, University of California, San Diego School of Medicine, La Jolla, CA


Jonathan M. Meyer, MD, is a graduate of Stanford University and Harvard Medical School and finished his adult psychiatry residency at Los Angeles County-USC Medical Center. At LA County-USC he subsequently completed fellowships in Consultation/Liaison Psychiatry and Psychopharmacology Research.

In addition to teaching duties at UC San Diego, Dr. Meyer has performed extensive research on the metabolic effects of antipsychotics, and the impact of antipsychotic medications on glucose-insulin homeostasis. Dr. Meyer has published numerous articles and book chapters on various aspects of antipsychotic psychopharmacology including the pharmacokinetics of oral and depot antipsychotics, metabolic effects of atypical antipsychotics, as well as on the health care outcomes in patients with severe mental illness.

Dr. Meyer is a national speaker about side effects and metabolic issues surrounding antipsychotic therapy, is chief editor of Medical Illness and Schizophrenia, now in its 2nd edition, and is the sole author of the chapter on the “Pharmacotherapy of Psychosis and Mania” in the last two editions of Goodman & Gilman's The Pharmacological Basis of Therapeutics.

read more +